Market Place
Sourcing Support
Rallybio Reports Q3 2024 Financial Results & Business Updates
07 Nov 2024 //
BUSINESSWIRE
Rallybio Approves Phase 2 Trial of RLYB212 for Pregnant Women
29 Oct 2024 //
BUSINESSWIRE
Rallybio To Present FNAIT Risk Analysis At ASHG 2024 Meeting
23 Sep 2024 //
BUSINESSWIRE
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
09 Sep 2024 //
BUSINESSWIRE
Rallybio to Present at Upcoming Investor Conferences
27 Aug 2024 //
BUSINESSWIRE
Rallybio Reports Q2 2024 Results And Business Updates
08 Aug 2024 //
BUSINESSWIRE
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
09 Jul 2024 //
BUSINESSWIRE
Rallybio Announces FNAIT Risk Analysis Across Diverse Populations
17 Jun 2024 //
BUSINESSWIRE
Rallybio Q1 2024 Financials, Business Update
09 May 2024 //
BUSINESSWIRE
Rallybio reigns in preclinical, Monopar pivots to radiopharma
09 May 2024 //
FIERCE BIOTECH
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
BUSINESSWIRE
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
26 Feb 2024 //
BUSINESSWIRE
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
06 Feb 2024 //
BUSINESSWIRE
Rallybio drops 45% of workforce to extend cash runway into 2026
06 Feb 2024 //
FIERCE BIOTECH
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
04 Jan 2024 //
BUSINESSWIRE
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116
20 Dec 2023 //
BUSINESSWIRE
Rallybio Announces Multiple Dose Data from the Completed Phase 1 of RLYB212
28 Nov 2023 //
BUSINESSWIRE
Rallybio Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
BUSINESSWIRE
Rallybio Announces Acceptance of FNAIT History Study Abstract for Presentation
02 Nov 2023 //
BUSINESSWIRE
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
03 Oct 2023 //
BUSINESSWIRE
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116
03 Sep 2023 //
BUSINESSWIRE
Rallybio to Present at Upcoming Investor Conferences in September
31 Aug 2023 //
BUSINESSWIRE
Rallybio Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
BUSINESSWIRE
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
02 Aug 2023 //
BUSINESSWIRE
Rallybio Announces Acceptance of Abstract for RLYB116 at ICW
11 Jul 2023 //
BUSINESSWIRE
Rallybio to Present at the Jefferies Healthcare Conference
01 Jun 2023 //
BUSINESSWIRE
Rallybio Reports First Quarter 2023 Financial Results
09 May 2023 //
BUSINESSWIRE
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211
06 Apr 2023 //
BUSINESSWIRE
Rallybio Announces Acceptance of Abstract for RLYB212 at ISTH
03 Apr 2023 //
BUSINESSWIRE
Rallybio Announces Proof-of-Concept Achieved for RLYB212
06 Mar 2023 //
BUSINESSWIRE
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
BUSINESSWIRE
Resolution Medical Appoints Peter Herman as Chief Executive Officer
06 Mar 2023 //
BUSINESSWIRE
Rallybio reassembles behind fetal blood disorder med 2.0
06 Mar 2023 //
FIERCE BIOTECH
Rallybio to Present at Upcoming Investor Conferences in March
01 Mar 2023 //
PRESS RELEASE
EyePoint & Rallybio Announce Collaboration to Evaluate Rallybio`s Inhibitor of C5
27 Feb 2023 //
BUSINESSWIRE
Rallybio Announces Publication Highlighting Ability of HPA-1a-Specific Antibodies
15 Dec 2022 //
BUSINESSWIRE
Rallybio revs up antibody discovery activities with risk-sharing AbCellera pact
02 Dec 2022 //
FIERCEBIOTECH
AbCellera and Rallybio Announce Strategic Alliance to Discover, Rare Diseases
01 Dec 2022 //
BUSINESSWIRE
Rallybio revs up antibody discovery activities in AbCellera pact
01 Dec 2022 //
FIERCEBIOTECH
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
29 Nov 2022 //
BUSINESSWIRE
Rallybio to Present at Upcoming Investor Conferences in November
11 Nov 2022 //
PRESS RELEASE
Rallybio Announces Proposed Public Offering
10 Nov 2022 //
PRESS RELEASE
Rallybio Announces Pricing of $50 Million Public Offering
10 Nov 2022 //
PRESS RELEASE
Rallybio Shares Plumb New Depths After Public Offering
10 Nov 2022 //
BUSINESSWIRE
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116
07 Nov 2022 //
BUSINESSWIRE
Rallybio Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Gamida Cell prices public offering at $20M; Rallybio touts PIb data for RLYB212
28 Sep 2022 //
ENDPTS
Rallybio Announces Retirement of Jeffrey Fryer, CPA, CFO
02 Jun 2022 //
PRESS RELEASE
Rallybio to Present at Upcoming Investor Conferences in June
01 Jun 2022 //
BUSINESSWIRE
Rallybio wades into Sanofi storeroom for $3M licensing deal
11 May 2022 //
FIERCEBIOTECH
Rallybio Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Board of Directors
04 Apr 2022 //
BUSINESSWIRE
Rallybio Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
BUSINESSWIRE
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
BUSINESSWIRE
Rallybio Reports Positive Data in Its Clinical Program for Thrombocytopenia
01 Dec 2021 //
BUSINESSWIRE
Rallybio Corporation Reports Second Quarter 2021 Financial Results
09 Sep 2021 //
BUSINESSWIRE
Almost six weeks after its IPO, RallyBio still struggling to find its footing
08 Sep 2021 //
SEEKING ALPHA
Rallybio Corporation Announces Closing of Initial Public Offering
02 Aug 2021 //
BUSINESS WIRE
Rallybio Corporation Announces Pricing of Initial Public Offering
29 Jul 2021 //
BUSINESSWIRE
